BRISTOL-MYERS SQUIBB CO (BMY) Stock Price, Forecast & Analysis
USA - NYSE:BMY - US1101221083 - Common Stock
BMY Key Statistics, Chart & Performance
The current stock price of BMY is 46.81 USD. In the past month the price increased by 7.39%. In the past year, price decreased by -20.49%.
BMY Latest News, Press Relases and Analysis
BMY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.46 | 967.00B | ||
| JNJ | JOHNSON & JOHNSON | 19.23 | 480.66B | ||
| MRK | MERCK & CO. INC. | 10.54 | 231.94B | ||
| PFE | PFIZER INC | 7.84 | 142.59B | ||
| ZTS | ZOETIS INC | 18.74 | 52.65B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.58 | 12.43B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.31 | 10.64B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.36 | 7.92B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.26B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.08B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.10B |
Related stock screener links
About BMY
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY 10016 US
CEO: Giovanni Caforio
Employees: 34100
Phone: 16092524621
BRISTOL-MYERS SQUIBB CO / BMY FAQ
Can you describe the business of BRISTOL-MYERS SQUIBB CO?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
What is the stock price of BRISTOL-MYERS SQUIBB CO today?
The current stock price of BMY is 46.81 USD. The price increased by 0.34% in the last trading session.
Does BMY stock pay dividends?
BRISTOL-MYERS SQUIBB CO (BMY) has a dividend yield of 5.1%. The yearly dividend amount is currently 2.42.
What is the ChartMill rating of BRISTOL-MYERS SQUIBB CO stock?
BMY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for BMY stock?
33 analysts have analysed BMY and the average price target is 52.67 USD. This implies a price increase of 12.51% is expected in the next year compared to the current price of 46.81.
Can you provide the growth outlook for BRISTOL-MYERS SQUIBB CO?
The Revenue of BRISTOL-MYERS SQUIBB CO (BMY) is expected to decline by -0.35% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (BMY) will report earnings on 2026-02-05, after the market close.
BMY Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to BMY. When comparing the yearly performance of all stocks, BMY is a bad performer in the overall market: 74.03% of all stocks are doing better.
BMY Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to BMY. While BMY has a great profitability rating, there are some minor concerns on its financial health.
BMY Financial Highlights
Over the last trailing twelve months BMY reported a non-GAAP Earnings per Share(EPS) of 6.56. The EPS increased by 460.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.57% | ||
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| Debt/Equity | 2.41 |
BMY Forecast & Estimates
33 analysts have analysed BMY and the average price target is 52.67 USD. This implies a price increase of 12.51% is expected in the next year compared to the current price of 46.81.
For the next year, analysts expect an EPS growth of 472.54% and a revenue growth -0.35% for BMY